Differential qualitative responses to rivastigmine in APOE ɛ4 carriers and noncarriers

Differential qualitative responses to rivastigmine in APOE ɛ4 carriers and noncarriers

ABSTRACT This retrospective analysis of two double-blind, placebo-controlled studies in patients with mild to moderately severe AD investigated the efficacy of rivastigmine 6–12 mg/day on cognitive outcomes in patients with or without the apolipoprotein (APOE) ɛ4 allele. APOE data were collected fro...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The pharmacogenomics journal 2004-09, Vol.4 (5), p.332-335
Hauptverfasser: Farlow, M, Lane, R, Kudaravalli, S, He, Y
Format: Artikel
Sprache:eng
Schlagworte:
Alzheimer's disease
Apolipoprotein E
Apolipoproteins
Biomedical and Life Sciences
Biomedicine
Cognitive ability
Gene Expression
Genotypes
Human Genetics
Neurodegenerative diseases
Oncology
original-article
Patients
Pharmacotherapy
Placebos
Psychopharmacology
Rivastigmine
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:ABSTRACT This retrospective analysis of two double-blind, placebo-controlled studies in patients with mild to moderately severe AD investigated the efficacy of rivastigmine 6–12 mg/day on cognitive outcomes in patients with or without the apolipoprotein (APOE) ɛ4 allele. APOE data were collected from patients who consented to pharmacogenetic testing. Treatment differences within each subgroup were compared, using the Observed Case (OC) population. The APOE ɛ4 and non-APOE ɛ4 subgroups comprised 246 and 121 patients, respectively. Overall, APOE ɛ4 noncarriers showed greater decline than carriers ( P
ISSN:1470-269X
1473-1150
DOI:10.1038/sj.tpj.6500267